LambdaVision Secures $7M Seed Funding to Advance Space-Manufactured Artificial Retina for Blindness Treatment
核心洞察
LambdaVision (搜索) has closed a $7 million seed funding round co-led by Seven Seven Six (搜索) and Aurelia Foundry (搜索) to advance clinical development of its protein-based artificial retina for treating retinal degenerative diseases (搜索).
The company's innovative artificial retina uses bacteriorhodopsin (搜索) proteins and is manufactured in microgravity aboard the International Space Station to achieve superior uniformity and optical quality compared to Earth-based production.
The funding, combined with over $18 million in previous NASA and government grants, will support operations through 2027 and advance the technology toward IND-enabling studies for retinitis pigmentosa (搜索) and age-related macular degeneration (搜索) patients.
LambdaVision (搜索), a Connecticut-based biotechnology company, has successfully closed a $7 million seed funding round to advance the clinical development of its groundbreaking protein-based artificial retina designed to restore vision in patients with retinal degenerative diseases (搜索). The funding round was co-led by Seven Seven Six (搜索), an early-stage venture capital firm, and Aurelia Foundry (搜索), a deep tech space fund, with additional participation from Seraphim Space (搜索), a major venture capital group specializing in the space sector.
The company, founded in 2018 and headquartered in Woodbridge, Connecticut, has developed a unique approach to treating blindness by leveraging space-based manufacturing to create artificial retinas for patients diagnosed with retinal degenerative diseases (搜索), including age-related macular degeneration (搜索) (AMD) and retinitis pigmentosa (搜索) (RP).
Revolutionary Space-Based Manufacturing Process
LambdaVision (搜索)'s artificial retina represents a significant departure from traditional electrode-based implants. The company's patent-protected technology uses proteins similar to the visual pigment rhodopsin (搜索) naturally found in human eyes, specifically utilizing bacteriorhodopsin (搜索) in a layer-by-layer manufacturing process alternated with polymers and supported by a synthetic fiber membrane.
The company has partnered with Space Tango (搜索), a Lexington, Kentucky-based aerospace company, to produce the artificial retina aboard the International Space Station (ISS) U.S. National Laboratory. To date, LambdaVision (搜索) has launched nine missions to the ISS, leveraging the microgravity environment to produce "highly uniform, 200-layer protein thin films" that are challenging to replicate on Earth.
According to the company, manufacturing in low-Earth orbit (LEO) "improves the homogeneity of the alternating protein and polymer layers" and enables increased stability, performance, and optical quality of the retina's multi-layer system. This space-based approach also potentially reduces material requirements, lowers costs, and accelerates production time for future preclinical and clinical efforts.
Technological Advantages Over Existing Solutions
Unlike traditional electrode-based implants that require external hardware to transmit and manipulate incoming signals and often result in low resolution, LambdaVision (搜索)'s artificial retina offers several key advantages. The device is powered by incident light and does not require "any external power supplies or bulky hardware on or outside the eye," according to the company.
Upon light absorption, the artificial retina generates "a unidirectional ion gradient" capable of stimulating the remaining neural circuitry of degenerated retinas. The company notes that its artificial retina has the potential for "far greater resolution" compared to existing electrode-based systems and is "being designed to work for anyone impacted by RP regardless of genotype."
Strong Financial Foundation and Government Support
The $7 million seed funding builds upon more than $18 million the company has previously received from NASA, the National Science Foundation, and the National Eye Institute. NASA and the ISS National Lab have contributed approximately $12 million in non-dilutive funding. This latest funding round provides LambdaVision (搜索) with sufficient capital to cover operating expenses into 2027.
The company recently received additional validation through a NASA Phase 2 In Space Production Applications (InSPA) award, marking it among the first recipients of this prestigious recognition. "This is among the first Phase 2 InSPA awards to be granted, marking an important milestone not only for LambdaVision (搜索) but for the broader goals of NASA's efforts to stimulate the development of a robust LEO economy," said Kevin Engelbert, InSPA portfolio manager.
Clinical Development Pathway
Dr. Nicole Wagner, CEO of LambdaVision (搜索), expressed gratitude for NASA's continued support, stating, "We are grateful that NASA continues to recognize the promise and impact of developing our artificial retina on the International Space Station, with the goal of not only offering much-needed benefit for patients with retinal degenerative diseases (搜索) here on Earth, but also laying the groundwork for other potential commercial efforts to manufacture therapies using a LEO platform."
The company's next milestone involves pursuing investigational new drug (IND)-enabling clinical trials for the artificial retina, which will be followed by clinical trials evaluating the device for RP patients and eventually AMD patients. The artificial retina is positioned to be "the first protein-based artificial retina" and aims to restore vision for patients who are blind or have lost significant sight due to these degenerative conditions.
Broader Implications for Space Commerce
LambdaVision (搜索)'s work represents a pioneering effort in the commercialization of space-based manufacturing for therapeutic applications. The company's layer-by-layer technology and manufacturing processes developed for LEO environments could potentially inspire new research and commercial product development, contributing to the development of a thriving LEO economy.
The InSPA program specifically supports U.S. companies working to advance commercial production of high-value materials and products in LEO, helping selected companies increase the technological readiness of their innovations and transition them toward market adoption. LambdaVision (搜索)'s artificial retina technology exemplifies "the transformative potential of manufacturing in microgravity to develop high-value, high-impact products that address critical human health challenges," according to Engelbert.